PTC Therapeutics, Inc. Shareholders' Equity
PTC Therapeutics, Inc. (PTCT) had Shareholders' Equity of -$165.36 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent -$165.36M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$180.47M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$205.31M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$155.76M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$165.36M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | -$180.47M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | -$205.31M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | -$155.76M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$206.55M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | -$185.76M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | -$1.10B 10-Q · filed 2026-07-30 | |
| 2024-09-30 | -$1.05B 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$980.18M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | -$893.92M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | -$818.55M 10-K · filed 2026-02-19 | |
| 2023-09-30 | -$670.81M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$579.27M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | -$457.56M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | -$347.09M 10-K · filed 2026-02-19 | |
| 2022-09-30 | -$226.90M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | -$182.22M 10-Q · filed 2023-10-26 | |
| 2022-03-31 | -$90.58M 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $1.44M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $104.93M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $196.58M 10-Q · filed 2022-10-27 | |
| 2021-03-31 | $292.58M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $481.98M 10-K · filed 2024-02-29 | |
| 2020-09-30 | $510.95M 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $572.49M 10-Q · filed 2021-10-28 | |
| 2020-03-31 | $528.73M 10-Q · filed 2021-07-29 | |
| 2019-12-31 | $594.33M 10-K · filed 2023-02-21 | |
| 2019-09-30 | $663.65M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $488.69M 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $512.94M 10-Q · filed 2020-08-05 | |
| 2018-12-31 | $350.73M 10-K · filed 2022-02-22 | |
| 2018-09-30 | $386.09M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $267.40M 10-Q · filed 2019-10-30 | |
| 2018-03-31 | $150.31M 10-Q · filed 2019-08-06 | $150.31M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $156.44M 10-K · filed 2021-02-25 | |
| 2017-09-30 | $145.88M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $169.73M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $100.83M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $119.58M 10-K · filed 2020-03-02 | |
| 2016-09-30 | $140.18M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $165.62M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $196.00M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $226.00M 10-K · filed 2019-03-01 | |
| 2015-09-30 | $269.15M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $248.58M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $273.32M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $298.47M 10-K · filed 2018-03-06 | |
| 2014-09-30 | $201.30M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $223.76M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $244.34M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $136.54M 10-K · filed 2017-03-16 | $136.54M 10-K · filed 2014-03-06 |
| 2013-09-30 | $151.03M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $152.92M 10-Q · filed 2013-08-13 | |
| 2012-12-31 | -$99.64M 10-K · filed 2016-02-29 | -$99.64M 10-Q · filed 2013-08-13 |
| 2011-12-31 | -$238.60M 10-K · filed 2015-03-02 | |
| 2010-12-31 | -$272.33M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |